. Author manuscript; available in PMC: 2022 Mar 1.

Published in final edited form as: J Thorac Cardiovasc Surg. 2020 Dec 17;161(3):836–843.e1. doi: 10.1016/j.jtcvs.2020.11.106

TABLE 2.

Thirty-day complications

Complication	Immune checkpoint inhibitor (n = 25)	Control (n = 143)	P value	Adjusted risk ratio (95% confidence interval)^*	Adjusted P value
Complication	n (%)		P value	Adjusted risk ratio (95% confidence interval)^*	Adjusted P value
Pulmonary	6 (24)	43 (30)	.6	0.96 (0.48-1.90)	.9
Major pulmonary	4 (16)	17 (12)	.5	1.43 (0.53-3.84)	.5
Cardiac	3 (12)	25 (17)	.8	1.07 (0.36-3.17)	.9
Major cardiac	0 (0)	2 (1.4)	1	–
Anastomotic	4 (16)	21 (15)	.8	1.16 (0.41-3.25)	.8
Major anastomotic	4 (16)	18 (13)	1	1.34 (0.45-3.94)	.6
Other	9 (36)	46 (32)	1	1.06 (0.57-1.99)	.8
Major other	2 (8.0)	8 (5.6)	.6	1.29 (0.26-6.28)	.8

Adjusted risk ratios were estimated only for outcomes with ≥10 events.